Route of Administration

How route of administration changes treatment delivery

Route of administration is the pathway by which a medicine is delivered to or into the body. It influences absorption, bioavailability, onset and duration, local and systemic adverse effects, dosing frequency, training, care setting, and resource use. This page explains the major routes and shows why route must be represented explicitly in clinical, pharmacoeconomic, and health-system decisions.

Route, dosage form, and device are different

The route identifies the anatomical pathway, while the dosage form describes the physical preparation and the device describes the delivery technology. A medicine can share one route across several formulations or devices with different performance and resource needs. These characteristics should be recorded separately to prevent clinically important differences from being hidden.

Element	What it describes	Example
Route	The pathway into or onto the body	Oral, intravenous, subcutaneous, inhaled, or topical
Dosage form	The physical preparation	Tablet, solution, suspension, patch, or powder
Device	The technology used to deliver the dose	Prefilled syringe, autoinjector, nebuliser, or inhaler
Setting	Where administration occurs	Home, community clinic, infusion centre, or hospital
Administrator	Who gives the medicine	Patient, caregiver, nurse, pharmacist, or physician

Enteral routes use the gastrointestinal pathway

Enteral administration includes oral, buccal, sublingual, and rectal routes. Oral treatment is often convenient and scalable, but absorption can be affected by food, gastrointestinal function, interactions, formulation, and first-pass metabolism. Buccal and sublingual delivery can provide more rapid absorption for suitable medicines, while rectal administration may be used when oral intake is not feasible.

Economic and practical considerations include storage, dosing frequency, swallowing ability, adherence, food restrictions, packaging, and whether administration can occur without clinical support.

Parenteral routes bypass the gastrointestinal tract

Parenteral administration includes intravenous, subcutaneous, intramuscular, intradermal, intrathecal, and other injection or infusion routes. These routes can provide rapid, controlled, or prolonged exposure and can be necessary when a medicine is not absorbed orally. They can also require sterile preparation, devices, trained staff, monitoring, and management of injection or infusion reactions.

The specific route matters: intravenous delivery provides direct systemic access, while subcutaneous or intramuscular delivery requires absorption from tissue. These routes should not be treated as interchangeable merely because each uses a needle.

Local routes target a body site

Topical, ophthalmic, otic, nasal, inhaled, vaginal, and other local routes aim to deliver medicine at or near the site of action. Local delivery can reduce systemic exposure, but technique, anatomy, formulation, and device performance affect the dose reaching the target. Some locally administered medicines still produce clinically important systemic exposure.

Evaluation should consider local tolerability, contamination, administration accuracy, training, cleaning, storage, and the ability of the intended patient or caregiver to use the product correctly.

Oral administration is convenient but not automatically simpler

Oral medicines often avoid visits and procedural costs, yet complex schedules, fasting requirements, pill burden, swallowing difficulty, nausea, malabsorption, or drug interactions can reduce effective use. The medicine's price may also shift from an institutional budget to a pharmacy or patient benefit. Convenience and affordability should therefore be measured rather than assumed.

Oral treatment may require monitoring, dispensing controls, adherence support, or safe handling. A tablet taken at home can generate substantial system and household costs when these requirements are included.

Intravenous administration provides controlled delivery

Intravenous administration places medicine directly into the circulation, giving complete systemic availability at the point of entry and permitting controlled infusion rates. It can support medicines requiring rapid effect, large volumes, or close observation. The route also introduces vascular-access, infection, extravasation, infusion-reaction, and capacity considerations.

Resource requirements can include:

• Pharmacy preparation and aseptic services.
• Infusion chair, bed, or treatment-room time.
• Nursing and medical supervision.
• Vascular access placement and maintenance.
• Premedication, laboratory testing, and observation.
• Travel, parking, waiting, and caregiver time.
• Management of reactions, line complications, and failed access.

Subcutaneous administration can shift care toward home

Subcutaneous administration delivers medicine into tissue beneath the skin for absorption into systemic circulation. Products can be given by a professional, patient, or caregiver depending on formulation, device, dose volume, and safety requirements. Switching from intravenous to subcutaneous delivery may reduce chair time but can transfer preparation, training, storage, and responsibility to the household.

The analysis should include injection frequency, device usability, local reactions, dose duration, refrigeration, sharps disposal, missed doses, and the proportion of patients able and willing to self-administer.

Intramuscular administration can provide rapid or depot delivery

Intramuscular injection can deliver vaccines, acute medicines, or long-acting depot formulations. Depot products may reduce dosing frequency and reveal adherence through attended administration, but they can also create prolonged adverse effects that cannot be reversed by stopping tablets. Clinic attendance, injection technique, pain, site reactions, and needle preferences affect acceptability.

Economic evaluation should distinguish the medicine's extended dosing interval from the appointment and observation requirements. A less frequent dose does not always mean less total burden.

Inhaled administration depends on device technique

Inhaled medicines deliver treatment to the respiratory tract through metered-dose inhalers, dry-powder inhalers, soft-mist devices, nebulisers, or other systems. Clinical effect depends on inspiratory ability, coordination, device preparation, cleaning, and adherence. Device switching can alter technique and outcomes even when the active ingredient is unchanged.

Assessment should include training, reassessment of technique, spacers or accessories, device availability, dose counters, maintenance, caregiver support, and environmental considerations. A low acquisition price can be false economy if poor technique reduces delivered dose and disease control.

Transdermal and implant routes can sustain exposure

Transdermal patches deliver medicine across the skin over time, while implants release medicine from a device placed in the body. These routes can reduce dosing frequency and fluctuations but introduce adhesion, skin, insertion, removal, and residual-drug issues. Heat, skin condition, body site, and device integrity can alter delivery.

The model should include insertion or removal procedures, device failure, premature discontinuation, reversibility, and the duration over which costs and effects accrue.

Bioavailability links route to systemic exposure

Bioavailability is the fraction of an administered dose that reaches systemic circulation unchanged. Intravenous administration is commonly used as the reference for absolute bioavailability. Oral and other extravascular routes can have incomplete absorption and presystemic metabolism.

Absolute bioavailability can be estimated from dose-normalised area under the concentration-time curve:

$$ F=\frac{AUC_{non-IV}}{AUC_{IV}}\times\frac{Dose_{IV}}{Dose_{non-IV}} $$

The estimate assumes comparable clearance and valid concentration-time data. A lower bioavailability does not automatically imply lower clinical effectiveness because the dose and formulation may be designed accordingly.

Relative bioavailability compares formulations or routes

Relative bioavailability compares systemic exposure between a test and reference product when an intravenous reference is not required. It can support bridging between formulations or devices. Comparable exposure does not by itself establish identical local effects, adherence, safety, or patient experience.

For dose-normalised exposure:

$$ F_{rel}=\frac{AUC_{test}}{AUC_{reference}}\times\frac{Dose_{reference}}{Dose_{test}} $$

Peak concentration, time to peak, partial exposure, and pharmacodynamic outcomes may also matter depending on the medicine and route.

Onset and duration affect value and use

Route can influence how quickly a medicine begins to act and how long clinically relevant exposure persists. Rapid onset can be valuable in emergencies or acute symptoms, while sustained delivery can reduce dosing frequency. Fast systemic entry can also increase acute adverse effects or monitoring needs.

Economic consequences can include avoided hospital time, earlier symptom relief, additional observation, reduced rescue medication, or prolonged management of adverse effects. These effects should be measured on a clinically relevant timescale.

First-pass metabolism affects some enteral medicines

Medicines absorbed from the gastrointestinal tract may pass through the liver before reaching systemic circulation, reducing or transforming the available dose. Sublingual, transdermal, inhaled, rectal, and parenteral routes can bypass some or all first-pass exposure depending on anatomy and product design. This pharmacological difference can change dose, interactions, and variability.

The economic model should use route-specific doses and outcomes rather than convert doses solely by acquisition price. Milligram-for-milligram comparisons may be meaningless across routes.

Administration time is a resource

Preparation, setup, delivery, observation, cleanup, and documentation all consume time. Published infusion duration alone can understate chair and staff use. Workflow studies should measure the complete episode and distinguish parallel from dedicated staff time.

Total administration time can be represented as:

$$ T_{episode}=T_{preparation}+T_{setup}+T_{delivery}+T_{observation}+T_{closure} $$

Not every component occupies the same resource. Pharmacy, nursing, chair, patient, and caregiver time should be costed separately when their opportunity costs differ.

Capacity constraints can change real-world value

An infusion centre with limited chairs or nurses may delay treatment or displace other patients. A route that shortens visits can release capacity, but released minutes create economic value only if they can be used productively or avoid expansion. Assuming every saved minute becomes a cash saving can overstate benefit.

Capacity analysis should examine demand by time of day, scheduling, setup, cancellations, observation, staffing ratios, bottlenecks, and the alternative use of released resources. Queueing or discrete-event simulation may be useful when timing and congestion determine access.

Home administration shifts resources and responsibility

Home administration can reduce travel and facility use while increasing patient or caregiver work. It may require training, refrigeration, storage, delivery coordination, sharps disposal, remote monitoring, and emergency support. Not every patient has a safe home, reliable supply chain, or willingness to self-administer.

The perspective should determine whether household time, equipment, utilities, and informal care are included. Equity analysis should identify who cannot benefit from the home route and ensure an accessible professional-delivery option remains available.

Route affects adherence and persistence

Frequent oral dosing, painful injections, long infusions, complex inhaler technique, or burdensome visits can reduce initiation, adherence, or persistence. Long-acting administration can simplify dosing but may require attendance and can reduce flexibility. Adherence should be defined appropriately for the route.

Useful measures include:

• Prescription initiation and abandonment.
• Proportion of doses taken or administrations attended.
• Correct device technique and successful dose delivery.
• Persistence to discontinuation.
• Delays, interruptions, and missed administration windows.
• Reasons for switching or stopping.

Patient preference can affect outcomes

People may value independence, rapid effect, fewer doses, professional supervision, discretion, avoidance of needles, or reduced travel differently. Preferences can influence uptake, adherence, anxiety, and satisfaction. A route should not be described as universally preferred from an average result.

Preference studies should present realistic information about frequency, duration, setting, efficacy, risks, monitoring, and cost. Hypothetical preferences may differ from choices after experience, and patients unable to use a route should not be treated as merely preferring another.

Caregiver burden can differ by route

Caregivers may organise transport, administer doses, monitor adverse effects, manage devices, store medicine, or supervise adherence. Moving treatment from clinic to home can transfer work without appearing in healthcare expenditure. The burden should be measured in time, health, and opportunity cost where relevant.

Caregiver effects can be positive when home care reduces travel and disruption, or negative when responsibility, anxiety, and technical tasks increase. Both directions should be considered.

Route-specific safety includes administration error

Safety depends on pharmacology and on how the medicine is prepared and delivered. Wrong route, concentration, rate, device, site, or technique can cause serious harm. Look-alike connectors, labelling, interruptions, and unfamiliar devices are system risks rather than individual failings alone.

Safety assessment should include:

• Local reactions, infection, tissue injury, and vascular complications.
• Systemic reactions related to rate or peak exposure.
• Preparation, dilution, compatibility, and stability errors.
• Device malfunction and use error.
• Wrong-route and wrong-site administration.
• Occupational exposure, sharps injury, and waste handling.
• Ability to stop or reverse delivery after an adverse event.

Formulation changes can alter route performance

Two products with the same active ingredient and route may differ in concentration, excipients, injection volume, delivery time, storage, stability, or device. These differences can affect safety, workflow, wastage, and preference. The analysis should identify the exact product rather than generalise from a route label.

When evidence is bridged across formulations, reviewers should examine pharmacokinetics, immunogenicity, administration success, clinical outcomes, and the intended population. Equivalence in one dimension should not be assumed in all others.

Route switching requires a defined protocol

Switching route can require dose conversion, timing relative to the previous dose, loading or observation, retraining, and monitoring. Clinical equivalence should be supported rather than inferred from convenience. Patients stable on one route may face different risks and preferences from treatment-naive patients.

A switching programme should specify eligibility, consent, exceptions, dosing, administration support, outcome monitoring, and a route back when the change is unsuccessful. Savings should be measured after accounting for implementation and switchback.

Route changes the full cost of treatment

Acquisition cost is only one component. Total cost can include preparation, consumables, device, administration, facility, monitoring, travel, patient and caregiver time, wastage, adverse events, and capacity. Costs should follow the frequency and duration of actual use.

For route (r), annual cost can be structured as:

$$ C_r=N_r\times(C_{drug,r}+C_{device,r}+C_{administration,r}+C_{monitoring,r})+C_{training,r}+C_{events,r} $$

where (N_r) is the number of administrations. One-off training and setup should not be multiplied in every cycle, while replacement training or device costs should be included when they recur.

Wastage depends on presentation and dosing

Fixed vial sizes, weight-based dosing, stability after opening, single-use devices, and missed appointments can create wastage. Sharing vials may reduce waste only when permitted, operationally feasible, and safe. Oral or self-administered medicines can also be wasted after discontinuation or delivery failure.

Expected drug used per administration can be distinguished from drug purchased:

$$ Wastage=Drug\ purchased-Drug\ administered $$

Costing should state assumptions about vial sharing, rounding, dose intensity, returns, and disposal. List-price comparisons that ignore wastage can misstate route differences.

Environmental effects can vary by route and device

Manufacture, cold-chain storage, transport, single-use devices, propellants, packaging, water, energy, and waste treatment can differ across routes. Environmental assessment should use a defined boundary and avoid assuming that home treatment is automatically lower impact. Patient travel may fall while deliveries and device waste rise.

Environmental effects can be reported separately or integrated through an approved framework. They should not be converted into health or monetary units without transparent methods and uncertainty.

Equity affects who can use each route

Route choice can interact with disability, dexterity, cognition, vision, literacy, language, housing, employment, transport, geography, insurance, and caregiver support. A route that reduces average cost can widen inequity if it depends on resources some patients do not have. Accessible alternatives and support should be part of implementation.

Equity analysis should examine:

• Access to administration sites and trained professionals.
• Out-of-pocket cost and benefit coverage by route.
• Ability to store, prepare, and administer treatment safely.
• Device accessibility and language-appropriate training.
• Travel, time off work, and caregiver requirements.
• Route uptake, successful administration, adherence, and outcomes by subgroup.

Clinical trials should separate route from treatment effect

When two products differ in active ingredient and route, observed outcomes combine pharmacological and delivery effects. Open-label route comparisons can also influence expectations, adherence, reporting, and co-interventions. Trials should measure administration success, preference, burden, and route-specific adverse events alongside clinical efficacy.

Non-inferiority designs used to compare a more convenient route require a justified margin, preserved assay sensitivity, adherence analysis, and attention to both intention-to-treat and per-protocol results. Convenience does not compensate for clinically important loss of effect unless the decision framework explicitly supports that trade-off.

Economic models should use route-specific pathways

Route affects treatment costs, adherence, adverse events, setting, capacity, utilities, and sometimes efficacy. Modelling only an administration cost difference can miss major consequences. The pathway should show who administers treatment, where, how often, for how long, and what happens after failure or switching.

Useful model inputs include:

• Dose, frequency, duration, and persistence.
• Product, device, consumables, and wastage.
• Preparation, administration, observation, and monitoring time.
• Setting and capacity constraints.
• Route-specific adverse events and administration failures.
• Patient and caregiver time and travel.
• Preference, utility, adherence, and switching effects.

Worked administration-cost example

Suppose an intravenous treatment is given 12 times per year. Each administration uses $40 of consumables, 90 minutes of chair time valued at $1.20 per minute, and 45 minutes of nursing time valued at $1.00 per minute. Excluding medicine, pharmacy preparation, travel, observation beyond the stated chair time, and overhead, annual administration cost is:

$$ C_{annual}=12\times[40+(90\times1.20)+(45\times1.00)] $$

$$ C_{annual}=12\times193=2{,}316 $$

The example illustrates resource costing, not a complete route comparison. Chair and nursing time may overlap, and released capacity does not necessarily become a cash saving.

Common mistakes

Route comparisons are often simplified to medicine price or dosing frequency. That can conceal clinically important exposure, device, workflow, and household consequences. The following errors should be checked before a route difference informs coverage or economic conclusions.

• Treating route, dosage form, device, setting, and administrator as the same characteristic.
• Assuming milligram doses are comparable across routes.
• Describing intravenous bioavailability as proof of superior effectiveness.
• Counting infusion time but omitting preparation, observation, and closure.
• Treating every saved staff minute as a recoverable financial saving.
• Assuming home administration eliminates rather than transfers resource use.
• Ignoring device technique, administration failure, and training.
• Assuming less frequent dosing always improves adherence or preference.
• Omitting patient travel, time, caregiver burden, and equity.
• Generalising evidence from one formulation or device to another without bridging evidence.

Reporting route of administration

Transparent reporting should identify the exact product and delivery pathway. Route labels alone are insufficient for replication or costing. The report should connect pharmacology, administration, patient experience, and resource use.

• State the active ingredient, formulation, concentration, route, device, dose, and frequency.
• State the administrator, setting, preparation, delivery, observation, and monitoring requirements.
• Report bioavailability, onset, duration, and relevant pharmacokinetic bridging evidence.
• Report administration success, technique, adherence, persistence, preference, and switching.
• Report route-specific adverse events, errors, and reversibility.
• Separate medicine, device, consumable, staff, facility, travel, time, wastage, and event costs.
• Describe capacity, equity, accessibility, environmental boundary, and uncertainty.
• Identify the product version, evidence date, price year, and implementation assumptions.

The decision standard

The best route is the one that delivers the intended clinical effect safely and reliably for the relevant patient while using health-system and household resources responsibly. No route is inherently more convenient, effective, or economical in every context. A credible comparison follows the complete pathway from dose and exposure through administration, adherence, outcomes, capacity, cost, preference, and equity.